Dates: 01/09/2016
31/08/2023
Topic: Biomarkers identification
Project type: Preclinic
Project target: Endocrine disease
Financing:
H2020-EU.3.1. – SOCIETAL CHALLENGES – Health; demographic change and well-being
H2020-EU.3.1.7. – Innovative Medicines Initiative 2 (IMI2)
Other
Participating agents:
LUNDS UNIVERSITET
-HELSINGIN YLIOPISTO
-ACADEMISCH ZIEKENHUIS GRONINGEN
-ITA-SUOMEN YLIOPISTO
-UNIVERSITY OF DUNDEE
-THE UNIVERSITY OF EXETER
-Istituto di Ricerche Farmacologiche Mario Negri
-TURUN YLIOPISTO
-VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA
-University of Bristol
-UNIVERSITY OF LEEDS
-THE LEEDS TEACHING HOSPITALS NATIONAL HEALTH SERVICE TRUST
-UNIVERSITY OF HULL
-CHU HOPITAUX DE BORDEAUX
-UNIVERSITATSKLINIKUM ERLANGEN
-MEDIZINISCHE UNIVERSITAT INNSBRUCK
-KLINIKUM DER UNIVERSITAET REGENSBURG
-MEDIZINISCHE UNIVERSITAET WIEN
-UNIVERSITA DEGLI STUDI DI BARI ALDO MORO
-APULIABIOTECH SOCIETA CONSORTILE AR L
-AZIENDA OSPEDALIERO UNIVERSITARIA CONSORZIALE POLICLINICO DI BARI
-LIPOTYPE
-UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN
-SIB SWISS INSTITUTE OF BIOINFORMATICS
-JDRF INTERNATIONAL
-ASTELLAS PHARMA EUROPE BV
-ELI LILLY AND COMPANY LTD
-NOVO NORDISK A/S
-BOEHRINGER INGELHEIM INTERNATIONAL GmbH
-UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
-ANTAROS MEDICAL AB
-THE UNIVERSITY OF SHEFFIELD
-BAYER AKTIENGESELLSCHAFT
Keywords: nephrology; diabetes; imaging techniques; biomarker; kidney model
Countries: Finland; Netherlands; UK; Italy; Germany; France; Austria; USA; Switzerland; Denmark; Sweden
Project page: Access page
